Mechanisms underlying latent disease risk associated with early-life arsenic exposure: Current research trends and scientific gaps. Bailey, K. A., Smith, A. H., Tokar, E. J., Graziano, J. H., Kim, K. W., Navasumrit, P., Fry, R. C. (2016). Environmental Health Perspectives, 124(2), 170-175.

28 Dec 2016
0
0

Mechanisms underlying latent disease risk associated with early-life arsenic exposure: Current research trends and scientific gaps.
Bailey, K. A., Smith, A. H., Tokar, E. J., Graziano, J. H., Kim, K. W., Navasumrit, P., Fry, R. C. (2016).
Environmental Health Perspectives, 124(2), 170-175.

Tags

Share this

Related Posts

An engineered cell line lacking OGG1 and MUTYH glycosylases implicates the accumulation of genomic 8-oxoguanine as the basis for paraquat mutagenicity. Tajai P, Fedeles BI, Suriyo T, Navasumrit P, Kanitwithayanun J, Essigmann JM, Satayavivad J. Free Radic Biol Med. 2018;116: 64-72.
20 Feb 2018
0

An engineered cell line lacking OGG1 and MUTYH glycosylases implicates the accumulation of genomic 8-oxoguanine as the basis for paraquat mutagenicity. Tajai P, Fedeles BI, Suriyo T, Navasumrit P, Kanitwithayanun J, Essigmann JM, Satayavivad J. Free Radic Biol Med. 2018;116: 64-72.

An engineered cell line lacking OGG1 and MUTYH glycosylases implicates the accumulation of genomic 8-oxoguanine as the basis for paraquat mutagenicity. Tajai P, Fedeles BI, Suriyo T, Navasumrit P, Kanitwithayanun J, Essigmann JM, Satayavivad J. Free Radic Biol Med. 2018;116: 64-72.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More